SCHEMBL4070832

SCHEMBL4070832

CN(Cc1ncc[nH]1)Cc1nccn1CC(=O)N1CCC2(CCNCC2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.39
KCNH2 Q12809 1/20 0.33
KDM1A O60341 1/20 0.32
MAOB P27338 1/20 0.32
RCOR1 Q9UKL0 1/20 0.32
OPRM1 P35372 3/20 0.32
OPRL1 P41146 3/20 0.32
HSD11B1 P28845 2/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
GABRD O14764 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRB2 P47870 1/20 0.31
GABRA4 P48169 1/20 0.31
NAMPT P43490 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073706 0.88 CXCR4 (0.51) CXCR4ALDH1A1
SCHEMBL4074526 0.87 CXCR4 (0.36) CXCR4KCNH2OPRM1OPRL1HSD11B1
SCHEMBL4067026 0.80 CXCR4 (0.42) CXCR4KDM1AMAOBRCOR1OPRM1
SCHEMBL4077666 0.80 CXCR4 (0.39) CXCR4OPRM1OPRL1
SCHEMBL4072232 0.80 CXCR4 (0.52) CXCR4ALDH1A1
SCHEMBL4068400 0.79 CXCR4 (0.49) CXCR4KDM1AMAOBRCOR1ALDH1A1
SCHEMBL4067775 0.79 CXCR4 (0.38) CXCR4OPRM1OPRL1
SCHEMBL4073802 0.79 CXCR4 (0.51) CXCR4ALDH1A1
SCHEMBL4070682 0.74 CXCR4 (0.46) CXCR4ALDH1A1
SCHEMBL4075810 0.74 CXCR4 (0.59) CXCR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2055705-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF Ono Pharmaceutical CO., LTD. (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF CXCR4, CXCL12, CXCR1 CXCR4 1/4885KCNH2 3961/4885KDM1A 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.